Abstract Library

#4520 Is late diagnosis and carcinoid heart disease (CaHD) associated with deprivation index? – An audit of practice and assessment of deprivation index in Sheffield ENETS Centre of Excellence

Introduction: Delays to diagnosis in neuroendocrine neoplasms is a world-wide problem. Challenges and inequities recognised include low awareness and access to expert centres. Indices of multiple deprivation (IMD) assess the least to the most deprived areas in the UK, 1 being the most deprived of the 10 deciles.

Conference:

Presenting Author: Munir A

Authors: Abdella O, Abdelhaleem E, Kwok W, Harber J, Rowett O,

Keywords: Index of multiple deprivation, carcinoid syndrome, carcinoid heart disease,

#4349 Challenging management of ductal adenocarcinoma of the prostate with neuroendocrine differentiation: A case report

Introduction: Ductal adenocarcinoma of the prostate is a rare subtype of prostate cancer that arises from the ducts of the prostate gland. It is characterised by distinct histological features and a more aggressive clinical course. Neuroendocrine differentiation within this subtype is associated with a more aggressive phenotype and can lead to resistance to conventional androgen deprivation therapies.

Conference:

Presenting Author:

Authors: Zerrouk D, Boukerzaza I, Laouar N, Kassama Z, Mansouri F,

Keywords: neuroendocrine prostate cancer, progression, multidisciplinary approach,

#4118 Adverse events after endoscopic ultrasound-guided fine-needle aspiration and fine-needle biopsy in pancreatic neuroendocrine tumors: A systematic review

Introduction: Pathological analysis of pancreatic neuroendocrine tumors (pNET) is essential for predicting tumor behaviour and patient management. Although endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is the established practice for retrieving tissue, fine-needle biopsy (EUS-FNB) offers possibilities for additional analyses including tumor grading. This systematic review provides a comprehensive evaluation of EUS-FNA and EUS-FNB-related adverse events in pNET.

Conference:

Presenting Author: Chen J

Authors: Chen J, Verschuur A, Abdelmonem A, Dreijerink K, Engelsman A,

Keywords: pancreatic neuroendocrine tumor, EUS-FNA, EUS-FNB, adverse events, systematic review,

#3815 Real-world observational study of somatostatin analogues and rescue medication use for neuroendocrine tumors in Canada

Introduction: Both octreotide long-acting release (OCT-LAR) and lanreotide autogel (LAN-ATG) are available in Canada for the management of neuroendocrine tumors (NETs). Patients can switch between SSAs due to effectiveness, adverse events (AEs), preference or reimbursement. For patients with functional disease, short acting SSAs can be used concomitantly as rescue medication to improve symptom control.

Conference:

Presenting Author:

Authors: Rayson D, Troesch M, Laforty C, Badin M, Liovas A,

Keywords: Neuroendocrine tumor, Somatostatin analogues, Lanreotide, Octreotide, SSA switch,

#3447 Access to diagnosis and treatments for patients with neuroendocrine tumors: A survey by the Brazilian Gastrointestinal Tumors Group

Introduction: While new treatments and diagnostic methods for patients (pts) with neuroendocrine neoplasms (NEN) have been incorporated, the extent of such access to Brazilian pts is unknown.

Conference:

Presenting Author:

Authors: Dias C, Peixoto R, Weschenfelder R, Prolla G, Rego J,

Keywords: neuroendocrine neoplasm, access, somatostatin analogues, public health,